Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Cami-T: promising results in classical Hodgkin lymphoma

Graham Collins • 20 Jun 2019
ICML 2019
Hodgkin Lymphoma Lymphoma Antibodies Camidanlumab tesirine

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the trial of camidanlumab tesirine (ADCT-301, Cami-T), an antibody-drug conjugate that binds to CD25, in relapsed/refractory classical Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Graham Collins

1:19
Mechanism of action of BTK degraders and insights into NX-5948
Graham Collins • 16 Jun 2023
1:15
The benefits of glofitamab in R/R DLBCL post-CAR-T therapy
Graham Collins • 16 Jun 2023
1:30
The role of tafasitamab in the lymphoma treatment landscape & promising results from clinical trials
Graham Collins • 16 Jun 2023
1:56
The future of bispecific antibodies in the treatment and management of R/R follicular lymphoma
Graham Collins • 16 Jun 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals